Our pipeline

Mereo Discover Our Pipeline

At Mereo, we unlock the potential of rare disease and tumor therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.

Our pipeline currently consists of six clinical-stage product candidates.

Core programs

We have already delivered three successful Phase 2 studies with a Phase 2 and Phase 1b/2 ongoing.

Product

Etigilimab (MPH313)

For patients with advanced or metastatic solid tumors

Product

Alvelestat (MPH966)

Lead indication: The treatment of severe Alpha-1 Antitrypsin Deficiency (“AATD”). Investigator led studies into additional indications ongoing. 

Product

Setrusumab (BPS804)

For the treatment of Osteogenesis Imperfecta (“OI”)

Core programs

Partnered and Partnering Opportunities on Non-Core Programs

We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna. 

Product

Navicixizumab (OMP305B83)

For the treatment of platinum-resistant ovarian cancer. Navicixizumab has been partnered with OncXerna Therapeutics Inc. for further development.

Product

Acumapimod (BCT197)

For the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).

Product

Leflutrozole (BGS649)

For the treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).

Partnered and partnering opportunities on non-core programs

Pipeline News

Image
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema
09 May 2022

Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema. 

Image
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
06 May 2022

 Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.

Image
Navicixizumab Phase 1b Data Has Been Published in the Journal of Clinical Oncology
22 April 2022

Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.

Image
Our Partner Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta
20 April 2022

Mereo BioPharma's partner for the development of setrusumab, Ultragenyx Pharmaceutical Inc. today announced the first patient has been dosed in a clinical study for the treatment of Osteogenesis Imperfecta (OI) in patients ages 5 to <26 years of age